TY - JOUR T1 - Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands JF - European Respiratory Journal JO - Eur Respir J SP - 1407 LP - 1416 DO - 10.1183/13993003.00325-2015 VL - 46 IS - 5 AU - Marie-Josée J. Mangen AU - Mark H. Rozenbaum AU - Susanne M. Huijts AU - Cornelis H. van Werkhoven AU - Douwe F. Postma AU - Mark Atwood AU - Anna M.M. van Deursen AU - Arie van der Ende AU - Diederick E. Grobbee AU - Elisabeth A.M. Sanders AU - Reiko Sato AU - Theo J.M. Verheij AU - Conrad E. Vissink AU - Marc J.M. Bonten AU - G. Ardine de Wit Y1 - 2015/11/01 UR - http://erj.ersjournals.com/content/46/5/1407.abstract N2 - The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65–74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750–17 100). Vaccination of high-risk individuals aged 65–74 years was cost-saving and extension to medium-risk individuals aged 65–74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.Vaccinating the elderly with 13-valent pneumococcal conjugate vaccine is highly cost-effective http://ow.ly/NVeui ER -